1. Home
  2. GCTK vs GRI Comparison

GCTK vs GRI Comparison

Compare GCTK & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GlucoTrack Inc.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$0.75

Market Cap

1.3M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.47

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
GRI
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3M
3.3M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
GCTK
GRI
Price
$0.75
$2.47
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
2.2M
67.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
31.22
N/A
Revenue
$589,462.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.18
52 Week High
$15.90
$6.70

Technical Indicators

Market Signals
Indicator
GCTK
GRI
Relative Strength Index (RSI) 35.55 52.42
Support Level $0.62 $2.16
Resistance Level $1.67 $2.66
Average True Range (ATR) 0.17 0.20
MACD 0.03 0.00
Stochastic Oscillator 8.66 53.03

Price Performance

Historical Comparison
GCTK
GRI

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: